Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLG Dose Study in GVHD Prophylaxis
NCT06525519Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of grafalon in graft-versus-host disease (GVHD), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
grafalon
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06525519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525519.